You are cordially invited to a royalty free SOFOSBUVIR VELPATASVIR **COMPULSORY LICENSE** When: NOW! Where: EVERYWHERE! RSVP to **#SofosbuvirParty**

The lifesaving combination of sofosbuvir (SOF) & velpatasvir (VEL) is recommended by WHO as pan genotypic regimen for the treatment and cure of HCV.

When Gilead launched SOF at USD 80,000 it shocked the world. The excessive price has wrecked health budgets and pushed people with HepC to run from country to country in their desperate bid to get hold of the drug.

Gilead's voluntary licenses on SOF & VEL exclude millions of patients in middle-income countries. These licenses are a smokescreen that in reality, create unfair monopolies where patents do not exist and where Gilead has no rights. When Ukraine tried to register a more affordable generic, Gilead sued them for millions of dollars.

Today while SOF is not widely patented & is being made by several generic companies, Gilead has instead filed patents on the SOF/VEL combination as a tactic to maintain their patent monopoly. Activists in several countries have filed patent oppositions on these patents, however in many middle-income countries they've been granted and the price set exorbitantly high.

We cannot wait any longer while Gilead abuses country patent systems to create unjustified monopolies. It is time for governments to join the party and revoke patents on SOF and SOF/VEL AND issue COMPULSORY LICENSES to ensure access to affordable generics for people with HCV NOW!

